PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
12677090-11	2002	Ad-E2F-1 treatment alone results in 3.4-fold increase of cyclin A kinase activity compared to Ad-LacZ control (p < 0.05); when combined with chemotherapeutic agents, cyclin A kinase activity was inhibited significantly by VIN, actinomycin D, and etoposide (p < 0.005), but not with CPT, CIS, and 5-FU (p > 0.1) compared to Ad-E2F-1 treatment alone.	Dactinomycin	230-243	cyclin A2	Homo sapiens	57-65	
12677090-11	2002	Ad-E2F-1 treatment alone results in 3.4-fold increase of cyclin A kinase activity compared to Ad-LacZ control (p < 0.05); when combined with chemotherapeutic agents, cyclin A kinase activity was inhibited significantly by VIN, actinomycin D, and etoposide (p < 0.005), but not with CPT, CIS, and 5-FU (p > 0.1) compared to Ad-E2F-1 treatment alone.	Dactinomycin	230-243	cyclin A2	Homo sapiens	169-177	
12677090-12	2002	Combination of Ad-LacZ/5-FU and Ad-LacZ/actinomycin D significantly inhibited cyclin A kinase activity compared to Ad-LacZ treatment alone (p < 0.005).	Dactinomycin	40-53	cyclin A2	Homo sapiens	78-86	
10844522-6	2000	Of note, mizoribine facilitated the degradation of cyclin A mRNA in the presence of actinomycin D, indicating that mizoribine shortens the stability of cyclin A mRNA.	Dactinomycin	84-97	cyclin A2	Homo sapiens	51-59